Cargando…

Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats

Myocardial ischemia-reperfusion (IR) injury contributes to adverse cardiac outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. In this study, we evaluated the ability of combined SS31-mitochondria (Mito) therapy to protect heart cells from myocardial IR injury. Adult male SD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Fan-Yen, Shao, Pei-Lin, Wallace, Christopher Glenn, Chua, Sarah, Sung, Pei-Hsun, Ko, Sheung-Fat, Chai, Han-Tan, Chung, Sheng-Ying, Chen, Kuan-Hung, Lu, Hung-I, Chen, Yi-Ling, Huang, Tien-Hung, Sheu, Jiunn-Jye, Yip, Hon-Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164143/
https://www.ncbi.nlm.nih.gov/pubmed/30223594
http://dx.doi.org/10.3390/ijms19092782
_version_ 1783359530034266112
author Lee, Fan-Yen
Shao, Pei-Lin
Wallace, Christopher Glenn
Chua, Sarah
Sung, Pei-Hsun
Ko, Sheung-Fat
Chai, Han-Tan
Chung, Sheng-Ying
Chen, Kuan-Hung
Lu, Hung-I
Chen, Yi-Ling
Huang, Tien-Hung
Sheu, Jiunn-Jye
Yip, Hon-Kan
author_facet Lee, Fan-Yen
Shao, Pei-Lin
Wallace, Christopher Glenn
Chua, Sarah
Sung, Pei-Hsun
Ko, Sheung-Fat
Chai, Han-Tan
Chung, Sheng-Ying
Chen, Kuan-Hung
Lu, Hung-I
Chen, Yi-Ling
Huang, Tien-Hung
Sheu, Jiunn-Jye
Yip, Hon-Kan
author_sort Lee, Fan-Yen
collection PubMed
description Myocardial ischemia-reperfusion (IR) injury contributes to adverse cardiac outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. In this study, we evaluated the ability of combined SS31-mitochondria (Mito) therapy to protect heart cells from myocardial IR injury. Adult male SD rats (n = 8/each group) were randomized: group 1 (sham-operated control), group 2 (IR, 30-min ischemia/72 h reperfusion), group 3 (IR-SS31 (2 mg intra-peritoneal injection at 30 min/24 h/48 h after IR)), group 4 (IR-mitochondria (2 mg/derived from donor liver/intra-venous administration/30 min after IR procedure)), and group 5 (IR-SS31-mitochondria). In H9C2 cells, SS31 suppressed menadione-induced oxidative-stress markers (NOX-1, NOX-2, oxidized protein) while it increased SIRT1/SIRT3 expression and ATP levels. In adult male rats 72 h after IR, left ventricular ejection fraction (LVEF) was highest in sham-operated control animals and lowest in the IR group. LVEF was also higher in IR rats treated with SS31-Mito than untreated IR rats or those treated with Mito or SS31 alone. Areas of fibrosis/collagen-deposition showed the opposite pattern. Likewise, levels of oxidative-stress markers (NOX-1, NOX-2, oxidized protein), inflammatory markers (MMP-9, CD11, IL-1β, TNF-α), apoptotic markers (mitochondrial-Bax, cleaved-caspase-3, PARP), fibrosis markers (p-Smad3, TGF-β), DNA-damage (γ-H2AX), sarcomere-length, and pressure/volume overload markers (BNP, β-MHC) all showed a pattern opposite that of LVEF. Conversely, anti-apoptotic (BMP-2, Smad1/5) and energy integrity (PGC-1α/mitochondrial cytochrome-C) markers exhibited a pattern identical to that of LVEF. This study demonstrates that the combined SS31-Mito therapy is superior to either therapy alone for protecting myocardium from IR injury and indicates that the responsible mechanisms involved increased SIRT1/SIRT3 expression, which suppresses inflammation and oxidative stress and protects mitochondrial integrity.
format Online
Article
Text
id pubmed-6164143
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61641432018-10-10 Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats Lee, Fan-Yen Shao, Pei-Lin Wallace, Christopher Glenn Chua, Sarah Sung, Pei-Hsun Ko, Sheung-Fat Chai, Han-Tan Chung, Sheng-Ying Chen, Kuan-Hung Lu, Hung-I Chen, Yi-Ling Huang, Tien-Hung Sheu, Jiunn-Jye Yip, Hon-Kan Int J Mol Sci Article Myocardial ischemia-reperfusion (IR) injury contributes to adverse cardiac outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. In this study, we evaluated the ability of combined SS31-mitochondria (Mito) therapy to protect heart cells from myocardial IR injury. Adult male SD rats (n = 8/each group) were randomized: group 1 (sham-operated control), group 2 (IR, 30-min ischemia/72 h reperfusion), group 3 (IR-SS31 (2 mg intra-peritoneal injection at 30 min/24 h/48 h after IR)), group 4 (IR-mitochondria (2 mg/derived from donor liver/intra-venous administration/30 min after IR procedure)), and group 5 (IR-SS31-mitochondria). In H9C2 cells, SS31 suppressed menadione-induced oxidative-stress markers (NOX-1, NOX-2, oxidized protein) while it increased SIRT1/SIRT3 expression and ATP levels. In adult male rats 72 h after IR, left ventricular ejection fraction (LVEF) was highest in sham-operated control animals and lowest in the IR group. LVEF was also higher in IR rats treated with SS31-Mito than untreated IR rats or those treated with Mito or SS31 alone. Areas of fibrosis/collagen-deposition showed the opposite pattern. Likewise, levels of oxidative-stress markers (NOX-1, NOX-2, oxidized protein), inflammatory markers (MMP-9, CD11, IL-1β, TNF-α), apoptotic markers (mitochondrial-Bax, cleaved-caspase-3, PARP), fibrosis markers (p-Smad3, TGF-β), DNA-damage (γ-H2AX), sarcomere-length, and pressure/volume overload markers (BNP, β-MHC) all showed a pattern opposite that of LVEF. Conversely, anti-apoptotic (BMP-2, Smad1/5) and energy integrity (PGC-1α/mitochondrial cytochrome-C) markers exhibited a pattern identical to that of LVEF. This study demonstrates that the combined SS31-Mito therapy is superior to either therapy alone for protecting myocardium from IR injury and indicates that the responsible mechanisms involved increased SIRT1/SIRT3 expression, which suppresses inflammation and oxidative stress and protects mitochondrial integrity. MDPI 2018-09-15 /pmc/articles/PMC6164143/ /pubmed/30223594 http://dx.doi.org/10.3390/ijms19092782 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Fan-Yen
Shao, Pei-Lin
Wallace, Christopher Glenn
Chua, Sarah
Sung, Pei-Hsun
Ko, Sheung-Fat
Chai, Han-Tan
Chung, Sheng-Ying
Chen, Kuan-Hung
Lu, Hung-I
Chen, Yi-Ling
Huang, Tien-Hung
Sheu, Jiunn-Jye
Yip, Hon-Kan
Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
title Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
title_full Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
title_fullStr Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
title_full_unstemmed Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
title_short Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats
title_sort combined therapy with ss31 and mitochondria mitigates myocardial ischemia-reperfusion injury in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164143/
https://www.ncbi.nlm.nih.gov/pubmed/30223594
http://dx.doi.org/10.3390/ijms19092782
work_keys_str_mv AT leefanyen combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT shaopeilin combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT wallacechristopherglenn combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT chuasarah combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT sungpeihsun combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT kosheungfat combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT chaihantan combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT chungshengying combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT chenkuanhung combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT luhungi combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT chenyiling combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT huangtienhung combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT sheujiunnjye combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats
AT yiphonkan combinedtherapywithss31andmitochondriamitigatesmyocardialischemiareperfusioninjuryinrats